FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1760323686> ?p ?o ?g. }

• W1760323686 abstract "Approximately 50% of patients with newly diagnosed non-small cell lung cancer (NSCLC) are over 70 years of age at diagnosis. Despite this fact, these patients are underrepresented in randomized controlled trials (RCTs). As a consequence, the most appropriate regimens for these patients are controversial, and the role of single-agent or combination therapy is unclear. In this setting, a critical systematic review of RCTs in this group of patients is warranted.To assess the effectiveness and safety of different cytotoxic chemotherapy regimens for previously untreated elderly patients with advanced (stage IIIB and IV) NSCLC. To also assess the impact of cytotoxic chemotherapy on quality of life.We searched the following electronic databases: Cochrane Central Register of Controlled Trials (CENTRAL; 2014, Issue 10), MEDLINE (1966 to 31 October 2014), EMBASE (1974 to 31 October 2014), and Latin American Caribbean Health Sciences Literature (LILACS) (1982 to 31 October 2014). In addition, we handsearched the proceedings of major conferences, reference lists from relevant resources, and the ClinicalTrial.gov database.We included only RCTs that compared non-platinum single-agent therapy versus non-platinum combination therapy, or non-platinum therapy versus platinum combination therapy in patients over 70 years of age with advanced NSCLC. We allowed inclusion of RCTs specifically designed for the elderly population and those designed for elderly subgroup analyses.Two review authors independently assessed search results, and a third review author resolved disagreements. We analyzed the following endpoints: overall survival (OS), one-year survival rate (1yOS), progression-free survival (PFS), objective response rate (ORR), major adverse events, and quality of life (QoL).We included 51 trials in the review: non-platinum single-agent therapy versus non-platinum combination therapy (seven trials) and non-platinum combination therapy versus platinum combination therapy (44 trials). Non-platinum single-agent versus non-platinum combination therapy Low-quality evidence suggests that these treatments have similar effects on overall survival (hazard ratio (HR) 0.92, 95% confidence interval (CI) 0.72 to 1.17; participants = 1062; five RCTs), 1yOS (risk ratio (RR) 0.88, 95% CI 0.73 to 1.07; participants = 992; four RCTs), and PFS (HR 0.94, 95% CI 0.83 to 1.07; participants = 942; four RCTs). Non-platinum combination therapy may better improve ORR compared with non-platinum single-agent therapy (RR 1.79, 95% CI 1.41 to 2.26; participants = 1014; five RCTs; low-quality evidence).Differences in effects on major adverse events between treatment groups were as follows: anemia: RR 1.10, 95% 0.53 to 2.31; participants = 983; four RCTs; very low-quality evidence; neutropenia: RR 1.26, 95% CI 0.96 to 1.65; participants = 983; four RCTs; low-quality evidence; and thrombocytopenia: RR 1.45, 95% CI 0.73 to 2.89; participants = 914; three RCTs; very low-quality evidence. Only two RCTs assessed quality of life; however, we were unable to perform a meta-analysis because of the paucity of available data. Non-platinum therapy versus platinum combination therapy Platinum combination therapy probably improves OS (HR 0.76, 95% CI 0.69 to 0.85; participants = 1705; 13 RCTs; moderate-quality evidence), 1yOS (RR 0.89, 95% CI 0.82 to 0.96; participants = 813; 13 RCTs; moderate-quality evidence), and ORR (RR 1.57, 95% CI 1.32 to 1.85; participants = 1432; 11 RCTs; moderate-quality evidence) compared with non-platinum therapies. Platinum combination therapy may also improve PFS, although our confidence in this finding is limited because the quality of evidence was low (HR 0.76, 95% CI 0.61 to 0.93; participants = 1273; nine RCTs).Effects on major adverse events between treatment groups were as follows: anemia: RR 2.53, 95% CI 1.70 to 3.76; participants = 1437; 11 RCTs; low-quality evidence; thrombocytopenia: RR 3.59, 95% CI 2.22 to 5.82; participants = 1260; nine RCTs; low-quality evidence; fatigue: RR 1.56, 95% CI 1.02 to 2.38; participants = 1150; seven RCTs; emesis: RR 3.64, 95% CI 1.82 to 7.29; participants = 1193; eight RCTs; and peripheral neuropathy: RR 7.02, 95% CI 2.42 to 20.41; participants = 776; five RCTs; low-quality evidence. Only five RCTs assessed QoL; however, we were unable to perform a meta-analysis because of the paucity of available data.In people over the age of 70 with advanced NSCLC who do not have significant co-morbidities, increased survival with platinum combination therapy needs to be balanced against higher risk of major adverse events when compared with non-platinum therapy. For people who are not suitable candidates for platinum treatment, we have found low-quality evidence suggesting that non-platinum combination and single-agent therapy regimens have similar effects on survival. We are uncertain as to the comparability of their adverse event profiles. Additional evidence on quality of life gathered from additional studies is needed to help inform decision making." @default.
• W1760323686 created "2016-06-24" @default.
• W1760323686 creator A5038413555 @default.
• W1760323686 creator A5055354449 @default.
• W1760323686 creator A5070778393 @default.
• W1760323686 creator A5070829374 @default.
• W1760323686 date "2015-10-20" @default.
• W1760323686 modified "2023-10-02" @default.
• W1760323686 title "Chemotherapy for advanced non-small cell lung cancer in the elderly population" @default.
• W1760323686 cites W1247968195 @default.
• W1760323686 cites W138119981 @default.
• W1760323686 cites W164508676 @default.
• W1760323686 cites W1898736255 @default.
• W1760323686 cites W1942409573 @default.
• W1760323686 cites W1966713566 @default.
• W1760323686 cites W1981153406 @default.
• W1760323686 cites W1985722827 @default.
• W1760323686 cites W1986670981 @default.
• W1760323686 cites W1991020867 @default.
• W1760323686 cites W1999129606 @default.
• W1760323686 cites W2004484157 @default.
• W1760323686 cites W2005529809 @default.
• W1760323686 cites W2007792079 @default.
• W1760323686 cites W2008274201 @default.
• W1760323686 cites W2024747530 @default.
• W1760323686 cites W2025937360 @default.
• W1760323686 cites W2026668567 @default.
• W1760323686 cites W2028796096 @default.
• W1760323686 cites W2028929367 @default.
• W1760323686 cites W2029363740 @default.
• W1760323686 cites W2030631654 @default.
• W1760323686 cites W2032551377 @default.
• W1760323686 cites W2034274383 @default.
• W1760323686 cites W2038155071 @default.
• W1760323686 cites W2038971960 @default.
• W1760323686 cites W2047072685 @default.
• W1760323686 cites W2048837261 @default.
• W1760323686 cites W2054175056 @default.
• W1760323686 cites W2055141641 @default.
• W1760323686 cites W2062054551 @default.
• W1760323686 cites W2070536874 @default.
• W1760323686 cites W2074190059 @default.
• W1760323686 cites W2075642745 @default.
• W1760323686 cites W2077520669 @default.
• W1760323686 cites W2082243542 @default.
• W1760323686 cites W2088095316 @default.
• W1760323686 cites W2089108918 @default.
• W1760323686 cites W2095992216 @default.
• W1760323686 cites W2096352516 @default.
• W1760323686 cites W2097268198 @default.
• W1760323686 cites W2098158939 @default.
• W1760323686 cites W2099072173 @default.
• W1760323686 cites W2100377347 @default.
• W1760323686 cites W2102621753 @default.
• W1760323686 cites W2104263235 @default.
• W1760323686 cites W2105304787 @default.
• W1760323686 cites W2108912949 @default.
• W1760323686 cites W2109015989 @default.
• W1760323686 cites W2110116826 @default.
• W1760323686 cites W2110586703 @default.
• W1760323686 cites W2111191667 @default.
• W1760323686 cites W2112089198 @default.
• W1760323686 cites W2115697715 @default.
• W1760323686 cites W2119321434 @default.
• W1760323686 cites W2120742888 @default.
• W1760323686 cites W2121095198 @default.
• W1760323686 cites W2123393316 @default.
• W1760323686 cites W2125357549 @default.
• W1760323686 cites W2129447971 @default.
• W1760323686 cites W2129793485 @default.
• W1760323686 cites W2132847057 @default.
• W1760323686 cites W2136419903 @default.
• W1760323686 cites W2137009016 @default.
• W1760323686 cites W2139248078 @default.
• W1760323686 cites W2140872365 @default.
• W1760323686 cites W2140884673 @default.
• W1760323686 cites W2145708032 @default.
• W1760323686 cites W2146463843 @default.
• W1760323686 cites W2147675681 @default.
• W1760323686 cites W2150358925 @default.
• W1760323686 cites W2151595445 @default.
• W1760323686 cites W2151986118 @default.
• W1760323686 cites W2153294383 @default.
• W1760323686 cites W2154948351 @default.
• W1760323686 cites W2156601859 @default.
• W1760323686 cites W2157784057 @default.
• W1760323686 cites W2159816656 @default.
• W1760323686 cites W2160131381 @default.
• W1760323686 cites W2162328883 @default.
• W1760323686 cites W2165048128 @default.
• W1760323686 cites W2167014559 @default.
• W1760323686 cites W2167600867 @default.
• W1760323686 cites W2170455685 @default.
• W1760323686 cites W2172028018 @default.
• W1760323686 cites W2172229147 @default.
• W1760323686 cites W2185481272 @default.
• W1760323686 cites W2256453366 @default.
• W1760323686 cites W2258616104 @default.
• W1760323686 cites W2331849216 @default.
• W1760323686 cites W2431827283 @default.

• next